Lmr Partners LLP Mirati Therapeutics, Inc. Transaction History

Lmr Partners LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $376,993 - $854,011	-9,627 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$75.82 - $150.97 $644,470 - $1.28 Million	-8,500 Reduced 46.89%	9,627 $792,000
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $2.13 Million - $3.06 Million	16,101 Added 794.72%	18,127 $2.66 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $1.17 Million - $1.58 Million	-8,884 Reduced 81.43%	2,026 $358,000
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $1.57 Million - $1.96 Million	10,910 New	10,910 $1.76 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.